Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Debt to Equity (2023 - 2024)

Iovance Biotherapeutics (IOVA) has disclosed Debt to Equity for 5 consecutive years, with $0.0 as the latest value for Q4 2024.

  • On a quarterly basis, Debt to Equity fell 17.71% to $0.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $0.0, a 17.71% decrease, with the full-year FY2024 number at $0.0, down 17.71% from a year prior.
  • Debt to Equity was $0.0 for Q4 2024 at Iovance Biotherapeutics, down from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.0 in Q2 2023 to a low of $0.0 in Q4 2024.